Huober et al [17] reported that only 19% of enrolled patients showed ER+ carcinoma, and a study with 3,348 MBC patients conducted in the USA [18] described similar low rates of ER and PR positivity (16.3% and 14%, respectively). The gene discussed is ESR1; the disease is carcinoma.